Mariam E. Morris

2017

In 2017, Mariam E. Morris earned a total compensation of $318.7K as Chief Financial Officer at Avalo Therapeutics, a 26% decrease compared to previous year.

Compensation breakdown

Option Awards$16,798
Salary$295,200
Other$6,718
Total$318,716

Morris received $295.2K in salary, accounting for 93% of the total pay in 2017.

Morris also received $16.8K in option awards and $6.7K in other compensation.

Rankings

In 2017, Mariam E. Morris' compensation ranked 13,186th out of 14,666 executives tracked by ExecPay. In other words, Morris earned more than 10.1% of executives.

ClassificationRankingPercentile
All
13,186
out of 14,666
10th
Division
Manufacturing
5,192
out of 5,772
10th
Major group
Chemicals And Allied Products
1,883
out of 2,075
9th
Industry group
Drugs
1,570
out of 1,731
9th
Industry
Pharmaceutical Preparations
1,214
out of 1,333
9th
Source: SEC filing on April 5, 2018.

Morris' colleagues

We found five more compensation records of executives who worked with Mariam E. Morris at Avalo Therapeutics in 2017.

2017

Uli Hacksell

Avalo Therapeutics

Chief Executive Officer

2017

Ronald Marcus

Avalo Therapeutics

Chief Medical Officer

2017

John Kaiser

Avalo Therapeutics

Chief Executive Officer

2017

Peter Greenleaf

Avalo Therapeutics

Chief Executive Officer

2017

Robert Moscato

Avalo Therapeutics

Chief Operating Officer

News

You may also like